← All trials
NCT05905783
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 22, 2023
- Primary completion
- Jun 14, 2025
- Completion date
- Dec 2, 2025
- First posted
- Jun 15, 2023
- Last posted
- Dec 15, 2023
- Enrollment
- 250
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- ACELYRIN Inc.Lead sponsor
- ACELYRIN Inc.Study director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.